Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole for prevention of ovarian hyperstimulation syndrome
IRCT20180313039085N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of letrozole in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Reduced occurrence of ovarian hyperstimulation syndrome. Started Mar 2020; status: completed.
02
Drugs
letrozole
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT20180313039085N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180313039085N1.